Sionna Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
SION$3.70+3.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit
(in thousands, except share amounts)
| Series Seed · Series A · Series B · Series C · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Deficit | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Preferred Stock · Preferred Stock · Preferred Stock · Common Stock | ||||||||||||||||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount | ||||||||||||||||||||||||||
| Balance at December 31, 2022 | 3,963,963 | $13,014 | 5,704,161 | $25,235 | 11,370,621 | $110,791 | — | — | 2,792,929 | $2 | $2,225 | $(16) | $(72,135) | $(69,924) | ||||||||||||
| Exercise of common stock options | — | — | — | — | — | — | — | — | 35,552 | — | 31 | — | — | 31 | ||||||||||||
| Vesting of restricted common stock awards | — | — | — | — | — | — | — | — | 222,382 | — | — | — | — | — | ||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | — | 2,259 | — | — | 2,259 | ||||||||||||
| Unrealized gain on marketable debt securities | — | — | — | — | — | — | — | — | — | — | — | 16 | — | 16 | ||||||||||||
| Net loss | — | — | — | — | — | — | — | — | — | — | — | — | (47,263) | (47,263) | ||||||||||||
| Balance at December 31, 2023 | 3,963,963 | $13,014 | 5,704,161 | $25,235 | 11,370,621 | $110,791 | — | — | 3,050,863 | $2 | $4,515 | $— | $(119,398) | $(114,881) | ||||||||||||
| Issuance of Series C Preferred Stock, net of issuance costs of $528 | — | — | — | — | — | — | 18,628,970 | 181,328 | — | — | — | — | — | — | ||||||||||||
| Issuance of common stock from IPR&D acquisition | — | — | — | — | — | — | — | — | 1,414,445 | 2 | 8,637 | 8,639 | ||||||||||||||
| Exercise of common stock options | — | — | — | — | — | — | — | — | 71,264 | 1 | 140 | — | — | 141 | ||||||||||||
| Vesting of restricted common stock awards | — | — | — | — | — | — | — | — | 186,191 | — | — | — | — | — | ||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | — | 3,708 | — | — | 3,708 | ||||||||||||
| Unrealized gain on marketable debt securities | — | — | — | — | — | — | — | — | — | — | — | 368 | — | 368 | ||||||||||||
| Net loss | — | — | — | — | — | — | — | — | — | — | — | — | (61,688) | (61,688) | ||||||||||||
| Balance at December 31, 2024 | 3,963,963 | $13,014 | 5,704,161 | $25,235 | 11,370,621 | $110,791 | 18,628,970 | $181,328 | 4,722,763 | $5 | $17,000 | $368 | $(181,086) | $(163,713) | ||||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.